TrialClinical cancer research : an official journal of the American Association for Cancer Research2020

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.

Mark R Middleton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.